1476. Respiratory Syncytial Virus-Associated Hospitalizations in Young Children in the United States, 2015–2016
Session: Poster Abstract Session: Pediatric Viral Infections
Friday, October 6, 2017
Room: Poster Hall CD
Posters
  • NVSN RSV IDWeek 2017 Poster.pdf (745.5 kB)
  • Background:

    Respiratory syncytial virus (RSV) is a major cause of severe acute respiratory illness (ARI) among young children. With several vaccines and immunoprophylaxis agents for RSV currently in development, updated estimates of severe RSV disease in young children in the United States (US) are needed.

    Methods:

    Prospective active surveillance for hospitalized ARI was conducted from 11/1/2015 to 6/30/2016 among children <5 years of age at seven pediatric hospital sites participating in the New Vaccine Surveillance Network. Demographic and clinical information for enrolled subjects were gathered through parent interviews and medical chart reviews. Mid-turbinate nasal and throat flocked swabs (combined for testing when available) and/or tracheal aspirates (when pertinent) were collected for respiratory pathogen testing. Specimens were tested for RSV using molecular diagnostic assays at each site.

    Results:

    In preliminary data analyses, 2,948 hospitalized children with a median age of 11 months were enrolled during the study period, of whom 1,030 (35%) tested positive for RSV. Most RSV-detections occurred in children <2 years of age (87%; n = 893), with 340 (33%) RSV-positive children aged 0–2 months, 184 (18%) aged 3–5 months, 174 (17%) aged 6–11 months, and 195 (19%) aged 12–23 months. The majority of RSV-positive children (75%; n = 776) had no chart-documented comorbid conditions. Among 893 RSV-positive children <2 years of age, 161 (18%) reported a history of preterm birth, with 99 (11%) reporting birth at 34–36 weeks gestational age (WGA), 33 (4%) at 30–33 WGA, 20 (2%) at <30 WGA, and 9 (1%) with no further gestational age information available. Among all RSV-positive subjects, the median length of stay was 2 days; 706 (69%) received supplemental oxygen during hospitalization, 226 (22%) were admitted to an intensive care unit, and 28 (3%) required mechanical ventilation.

    Conclusion:

    During the 2015–16 season, RSV was associated with one third of ARI hospitalizations in young children, the majority of which occurred in children aged <2 years. Most RSV-positive children were previously healthy, and nearly one fifth of those <2 years of age reported a history of preterm birth. RSV continues to be a major cause of morbidity among young children in the US.

    Brian Rha, MD, MSPH1, Angela P. Campbell, MD, MPH, FPIDS, FIDSA2, Darius McDaniel, MSPH1, Geoffrey A. Weinberg, MD, FIDSA, FPIDS3, Mary A. Staat, M.D., M.P.H.4, Rangaraj Selvarangan, PhD5, Natasha B. Halasa, MD, MPH, FPIDS6, Janet Englund, MD, FIDSA7, Julie A. Boom, MD8, Parvin H. Azimi, MD9, John V. Williams, MD10, Peter G. Szilagyi, MD, MPH11,12, Monica N. Singer, MD, MPH13, Flor M. Munoz, MD14, Monica Mcneal, MS15, Eileen J. Klein, MD, MPH7, Christopher J. Harrison, M.D., FAAP, FPIDS16, Daniella Figueroa-Downing, MPH1, Joana Yu, MPH1,17, Mila M. Prill, MSPH1, Brett L. Whitaker, MS1, Aaron T. Curns, MPH1, Daniel C. Payne, PhD, MSPH18 and Susan I. Gerber, MD1, (1)Division of Viral Diseases, Centers for Disease Control and Prevention, Atlanta, GA, (2)Influenza Division, Centers for Disease Control and Prevention, Atlanta, GA, (3)Univ. of Rochester Sch. of Medicine and Dentistry, Rochester, NY, (4)Cincinnati Children's Hospital Medical Center, Cincinnati, OH, (5)Microbiology Laboratory, Children's Mercy Hospital and Clinics, Kansas City, MO, (6)Vanderbilt University Medical Center, Nashville, TN, (7)University of Washington/Seattle Children's Hospital, Seattle, WA, (8)Texas Children's Hospital, Houston, TX, (9)UCSF Benioff Children's Hospital Oakland, Oakland, CA, (10)Children's Hospital of Pittsburgh, Pittsburgh, PA, (11)University of Rochester School of Medicine, Rochester, NY, (12)University of California at Los Angeles, Los Angeles, CA, (13)UCSF Benioff Children’s Hospital Oakland, Oakland, CA, (14)Pediatric Infectious Diseases, Baylor College of Medicine, Texas Children's Hospital, Houston, TX, (15)Division of Infectious Diseases, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, (16)Children's Mercy Hospital and Clinics, Kansas City, MO, (17)IHRC, Atlanta, GA, (18)Centers for Disease Control and Prevention, Atlanta, GA

    Disclosures:

    B. Rha, None

    A. P. Campbell, None

    D. McDaniel, None

    G. A. Weinberg, None

    M. A. Staat, None

    R. Selvarangan, None

    N. B. Halasa, Sanofi Pasteur: Research Contractor , Research support
    Astra Zeneca: Research Contractor , Grant recipient

    J. Englund, Gilead: Consultant and Investigator , Research support
    Chimerix: Investigator , Research support
    Alios: Investigator , Research support
    Novavax: Investigator , Research support
    MedImmune: Investigator , Research support
    GlaxoSmithKline: Investigator , Research support

    J. A. Boom, None

    P. H. Azimi, None

    J. V. Williams, Quidel: Scientific Advisor , Consulting fee
    GlaxoSmithKline: Scientific Advisor , Consulting fee

    P. G. Szilagyi, None

    M. N. Singer, None

    F. M. Munoz, Novavax: Investigator , Research support
    Regeneron: Investigator , Research support
    GSK: Investigator , Research support

    M. Mcneal, None

    E. J. Klein, None

    C. J. Harrison, None

    D. Figueroa-Downing, None

    J. Yu, None

    M. M. Prill, None

    B. L. Whitaker, None

    A. T. Curns, None

    D. C. Payne, None

    S. I. Gerber, None

    Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 4th with the exception of research findings presented at the IDWeek press conferences.